Tideglusib for congenital myotonic dystrophy
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial provides access to a medication called tideglusib for people with congenital myotonic dystrophy. The goal is to see if it helps with symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of congenital myotonic dystrophy.
- You must be able to travel to a participating study site.
- You must be willing to follow the study's rules and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how safe and effective tideglusib is for children and young adults with congenital or childhood-onset myotonic dystrophy type 1 (DM1). It may help researchers learn whether the medicine improves symptoms while tracking side effects closely.
This study looks at how to best measure muscle health and function in children with myotonic dystrophy. It may help prepare for future treatment trials.
This study builds a registry of people and families affected by myotonic dystrophy types 1 and 2. It helps researchers learn about the condition over time and may support future studies that could lead to better care.
This trial tests whether an experimental drug called tideglusib can slow the progression of ALS. It is for people with a recent ALS diagnosis whose breathing is still fairly strong.
This trial tests a medication called tideglusib to see if it can reduce extra heartbeats in people with a genetic form of arrhythmogenic cardiomyopathy. It may help stabilize the heart's rhythm and slow disease progression.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
Hear when a new Congenital Myotonic Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.